Compare Fresenius Kabi Onco. with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs STERLING BIOTECH - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. STERLING BIOTECH FRESENIUS KABI ONCO./
STERLING BIOTECH
 
P/E (TTM) x 22.1 -0.4 - View Chart
P/BV x 3.1 0.0 21,848.6% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 FRESENIUS KABI ONCO.   STERLING BIOTECH
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
STERLING BIOTECH
Dec-13
FRESENIUS KABI ONCO./
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs17611 1,676.2%   
Low Rs793 2,308.8%   
Sales per share (Unadj.) Rs37.726.8 140.6%  
Earnings per share (Unadj.) Rs5.1-15.0 -34.1%  
Cash flow per share (Unadj.) Rs6.7-5.5 -123.1%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs42.554.9 77.5%  
Shares outstanding (eoy) m158.23267.87 59.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.40.3 1,302.4%   
Avg P/E ratio x25.0-0.5 -5,376.8%  
P/CF ratio (eoy) x18.9-1.3 -1,487.7%  
Price / Book Value ratio x3.00.1 2,361.9%  
Dividend payout %00-   
Avg Mkt Cap Rs m20,1351,862 1,081.5%   
No. of employees `0001.21.4 85.1%   
Total wages/salary Rs m703547 128.6%   
Avg. sales/employee Rs Th5,176.25,303.3 97.6%   
Avg. wages/employee Rs Th610.4403.8 151.2%   
Avg. net profit/employee Rs Th699.6-2,959.0 -23.6%   
INCOME DATA
Net Sales Rs m5,9637,181 83.0%  
Other income Rs m1843 42.3%   
Total revenues Rs m5,9817,223 82.8%   
Gross profit Rs m1,430947 151.0%  
Depreciation Rs m2582,543 10.1%   
Interest Rs m-264,377 -0.6%   
Profit before tax Rs m1,216-5,931 -20.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m342-1,924 -17.8%   
Profit after tax Rs m806-4,007 -20.1%  
Gross profit margin %24.013.2 181.9%  
Effective tax rate %28.132.4 86.7%   
Net profit margin %13.5-55.8 -24.2%  
BALANCE SHEET DATA
Current assets Rs m5,10214,335 35.6%   
Current liabilities Rs m2,38549,809 4.8%   
Net working cap to sales %45.6-494.0 -9.2%  
Current ratio x2.10.3 743.1%  
Inventory Days Days150403 37.2%  
Debtors Days Days113171 66.4%  
Net fixed assets Rs m5,14855,432 9.3%   
Share capital Rs m158268 59.1%   
"Free" reserves Rs m6,55613,935 47.0%   
Net worth Rs m6,73214,701 45.8%   
Long term debt Rs m9529,478 10.0%   
Total assets Rs m10,38873,988 14.0%  
Interest coverage x-45.8-0.4 12,896.3%   
Debt to equity ratio x0.10.6 21.9%  
Sales to assets ratio x0.60.1 591.5%   
Return on assets %7.50.5 1,498.9%  
Return on equity %12.0-27.3 -43.9%  
Return on capital %14.6-6.4 -227.3%  
Exports to sales %74.525.9 287.5%   
Imports to sales %24.80.2 14,582.8%   
Exports (fob) Rs m4,4411,860 238.8%   
Imports (cif) Rs m1,47712 12,109.8%   
Fx inflow Rs m5,2981,860 284.8%   
Fx outflow Rs m1,77225 7,120.1%   
Net fx Rs m3,5251,835 192.1%   
CASH FLOW
From Operations Rs m1,2741,719 74.1%  
From Investments Rs m-1,204-3,148 38.3%  
From Financial Activity Rs m-1961,426 -13.8%  
Net Cashflow Rs m-126-3 3,714.7%  

Share Holding

Indian Promoters % 0.0 33.9 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.0 -  
FIIs % 9.6 9.9 97.0%  
ADR/GDR % 0.0 16.9 -  
Free float % 9.1 39.3 23.2%  
Shareholders   42,599 21,482 198.3%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   NATCO PHARMA  PANACEA BIOTECH  WOCKHARDT  ABBOTT INDIA  PLETHICO PHARMA  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Gains; Tata Motors & ONGC Climb 5%(12:30 pm)

Share markets in India have extended early morning gains and are presently trading higher. Investors are cautious ahead of the release of Consumer Price Index-based inflation.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Foreign Money is Chasing Indian Stocks Once Again(The 5 Minute Wrapup)

Oct 4, 2019

Around Rs 75 billion poured into the Indian stock market in the month of September.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS